Lantheus Holdings Inc
LNTH66.570USD
-0.050-0.08%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
4.41BMarket Cap
27.02P/E TTM
More Details of Lantheus Holdings Inc Company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Lantheus Holdings Inc Info
Ticker SymbolLNTH
Company nameLantheus Holdings Inc
IPO dateJun 25, 2015
CEOMarkison (Brian A)
Number of employees808
Security typeOrdinary Share
Fiscal year-endJun 25
Address331 Treble Cove Road
CityNORTH BILLERICA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01862
Phone19786718001
Websitehttps://www.lantheus.com/
Ticker SymbolLNTH
IPO dateJun 25, 2015
CEOMarkison (Brian A)
Company Executives of Lantheus Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
599.01K
+2.44%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Jamie Spaeth
Ms. Jamie Spaeth
Chief People Officer
Chief People Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
599.01K
+2.44%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
250.64M
0.00%
DEFINITY
83.94M
0.00%
TechneLite
24.98M
0.00%
Strategic partnerships and other
11.59M
0.00%
Other precision diagnostics
6.89M
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
250.64M
0.00%
DEFINITY
83.94M
0.00%
TechneLite
24.98M
0.00%
Strategic partnerships and other
11.59M
0.00%
Other precision diagnostics
6.89M
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.00%
The Vanguard Group, Inc.
10.44%
Janus Henderson Investors
10.08%
Morgan Stanley & Co. LLC
5.55%
Farallon Capital Management, L.L.C.
5.24%
Other
57.69%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.00%
The Vanguard Group, Inc.
10.44%
Janus Henderson Investors
10.08%
Morgan Stanley & Co. LLC
5.55%
Farallon Capital Management, L.L.C.
5.24%
Other
57.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.54%
Investment Advisor/Hedge Fund
36.56%
Research Firm
8.90%
Hedge Fund
8.13%
Individual Investor
2.40%
Pension Fund
1.80%
Bank and Trust
0.94%
Sovereign Wealth Fund
0.77%
Family Office
0.09%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1018
78.96M
119.07%
-8.67M
2025Q2
1039
82.20M
120.88%
-4.84M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.50M
11.03%
-294.68K
-3.78%
Jun 30, 2025
The Vanguard Group, Inc.
6.82M
10.03%
-163.58K
-2.34%
Jun 30, 2025
Janus Henderson Investors
6.94M
10.21%
+677.11K
+10.81%
Jun 30, 2025
Farallon Capital Management, L.L.C.
3.32M
4.88%
-3.41M
-50.67%
Aug 20, 2025
Fidelity Management & Research Company LLC
4.13M
6.08%
+1.96M
+90.51%
Jun 30, 2025
State Street Investment Management (US)
2.56M
3.76%
-76.88K
-2.92%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.78M
2.61%
-532.00
-0.03%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.38M
2.03%
+4.59K
+0.33%
Jun 30, 2025
Reinhart Partners, LLC
1.40M
2.06%
+197.72K
+16.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Health Care Equipment ETF
1.96%
Invesco S&P MidCap 400 GARP ETF
1.69%
First Trust Small Cap US Equity Select ETF
1.07%
VictoryShares Small Cap Free Cash Flow ETF
0.93%
Invesco S&P MidCap 400 Pure Growth ETF
0.74%
Distillate Small/Mid Cash Flow ETF
0.66%
Pacer US Small Cap Cash Cows ETF
0.56%
Gotham 1000 Value ETF
0.5%
Invesco S&P MidCap Quality ETF
0.47%
Pacer US Cash Cows Growth ETF
0.47%
View more
State Street SPDR S&P Health Care Equipment ETF
Proportion1.96%
Invesco S&P MidCap 400 GARP ETF
Proportion1.69%
First Trust Small Cap US Equity Select ETF
Proportion1.07%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.93%
Invesco S&P MidCap 400 Pure Growth ETF
Proportion0.74%
Distillate Small/Mid Cash Flow ETF
Proportion0.66%
Pacer US Small Cap Cash Cows ETF
Proportion0.56%
Gotham 1000 Value ETF
Proportion0.5%
Invesco S&P MidCap Quality ETF
Proportion0.47%
Pacer US Cash Cows Growth ETF
Proportion0.47%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Lantheus Holdings Inc?
The top five shareholders of Lantheus Holdings Inc are:
BlackRock Institutional Trust Company, N.A. holds 7.50M shares, accounting for 11.03% of the total shares.
The Vanguard Group, Inc. holds 6.82M shares, accounting for 10.03% of the total shares.
Janus Henderson Investors holds 6.94M shares, accounting for 10.21% of the total shares.
Farallon Capital Management, L.L.C. holds 3.32M shares, accounting for 4.88% of the total shares.
Fidelity Management & Research Company LLC holds 4.13M shares, accounting for 6.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.50M shares, accounting for 11.03% of the total shares.
The Vanguard Group, Inc. holds 6.82M shares, accounting for 10.03% of the total shares.
Janus Henderson Investors holds 6.94M shares, accounting for 10.21% of the total shares.
Farallon Capital Management, L.L.C. holds 3.32M shares, accounting for 4.88% of the total shares.
Fidelity Management & Research Company LLC holds 4.13M shares, accounting for 6.08% of the total shares.
What are the top three shareholder types of Lantheus Holdings Inc?
The top three shareholder types of Lantheus Holdings Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Janus Henderson Investors
How many institutions hold shares of Lantheus Holdings Inc (LNTH)?
As of 2025Q3, 1018 institutions hold shares of Lantheus Holdings Inc, with a combined market value of approximately 78.96M, accounting for 119.07% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.81%.
What is the biggest source of revenue for Lantheus Holdings Inc?
In FY2025Q2, the PYLARIFY business generated the highest revenue for Lantheus Holdings Inc, amounting to 250.64M and accounting for --% of total revenue.
